Yield10 Bioscience Announces Closing of $12.7 Million Public Offering

By Dr. Matthew Watson

WOBURN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share. Gross proceeds before deducting underwriting discounts and commissions and other offering expenses are approximately $12.7 million. Existing investors, including shareholder Jack W. Schuler, as well as institutional and retail investors participated in the offering.

Read more here:
Yield10 Bioscience Announces Closing of $12.7 Million Public Offering

Related Post


categoriaGlobal News Feed commentoComments Off on Yield10 Bioscience Announces Closing of $12.7 Million Public Offering | dataFebruary 3rd, 2021

About...

This author published 5432 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024